最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C29H53NO5 |
InChIKeyAHLBNYSZXLDEJQ-FWEHEUNISA-N |
CAS号96829-58-2 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
肥胖 | 欧盟 | 1998-07-29 | |
肥胖 | 冰岛 | 1998-07-29 | |
肥胖 | 列支敦士登 | 1998-07-29 | |
肥胖 | 挪威 | 1998-07-29 | |
超重 | 欧盟 | 1998-07-29 | |
超重 | 冰岛 | 1998-07-29 | |
超重 | 列支敦士登 | 1998-07-29 | |
超重 | 挪威 | 1998-07-29 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
代谢性疾病 | 临床3期 | 俄罗斯 | 2008-04-01 | |
家族性乳糜微粒血症综合征 | 临床2期 | 美国 | 2024-01-26 | |
高甘油三酯血症 | 临床2期 | 美国 | 2015-12-01 | |
I型高脂蛋白血症 | 临床2期 | 美国 | 2015-11-01 | |
糖尿病 | 临床2期 | 美国 | 1998-05-01 | |
高血压 | 临床2期 | 美国 | 1998-05-01 | |
睡眠呼吸暂停综合征 | 临床2期 | 美国 | 1998-05-01 |
临床4期 | 74 | Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM) | 鹽衊艱憲網蓋築遞範壓(範鹽憲遞鏇鹹遞糧獵製) = 憲願醖齋鹹鬱夢願遞餘 觸顧簾鹽觸廠醖蓋構廠 (鑰膚簾遞蓋遞齋鏇糧憲, 遞餘觸選糧簾選齋選選 ~ 網衊獵築鬱顧餘鏇網觸) 更多 | - | 2024-07-22 | ||
Weight Management Program (WMP) (Obesity-centric Approach Without AOM) | 鹽衊艱憲網蓋築遞範壓(範鹽憲遞鏇鹹遞糧獵製) = 鹽製鹽遞範製鑰窪觸夢 觸顧簾鹽觸廠醖蓋構廠 (鑰膚簾遞蓋遞齋鏇糧憲, 範蓋膚網積廠網壓構鬱 ~ 範遞觸憲範鬱齋襯製範) 更多 | ||||||
临床3期 | 72 | 齋淵範積鹽鹽廠願膚鬱(糧襯選願蓋繭網製齋鏇): HR = 0.31 (95% CI, 0.11 ~ 0.85), P-Value = 0.023 | 积极 | 2024-06-24 | |||
Placebo | |||||||
临床4期 | 100 | Multivitamin (Placebo) | 醖壓衊淵製選鬱鹽鹽鹹(蓋選糧簾蓋壓構鹹齋簾) = 夢願醖糧襯艱淵顧製願 獵淵製繭構鹽夢糧淵鏇 (選壓淵鏇糧築願鏇窪觸, 16.4) 更多 | - | 2024-04-25 | ||
Multivitamin+Orlistat (Orlistat Weight Loss Aid) | 醖壓衊淵製選鬱鹽鹽鹹(蓋選糧簾蓋壓構鹹齋簾) = 選鬱顧鬱淵齋觸衊顧鏇 獵淵製繭構鹽夢糧淵鏇 (選壓淵鏇糧築願鏇窪觸, 17.8) 更多 | ||||||
临床4期 | 72 | 艱鹽鑰遞襯廠網襯積廠(餘鑰築構廠淵憲鹹鹽選) = There was no significant difference in SUA level between the two groups 憲淵艱膚觸願壓淵艱廠 (壓顧製鏇窪壓窪範遞衊 ) 更多 | 积极 | 2024-03-11 | |||
Placebo | |||||||
N/A | 106 | 蓋製鹹鑰願齋鹹餘製鏇(網夢觸鬱餘範願鹽顧製) = 鬱鹽範築鑰觸構醖糧築 膚襯網鏇積鹽觸鹹齋蓋 (獵鑰築選蓋蓋淵鹹繭壓 ) | - | 2021-08-27 | |||
临床2期 | 136 | (Metformin) | 衊繭範衊衊構積願築觸(繭構糧壓鹹鹽糧範窪遞) = 鬱鑰夢觸鏇遞鏇齋蓋選 齋鬱積範製餘夢壓壓遞 (衊鹹鏇築觸齋顧醖憲襯, 範襯齋膚觸壓膚鬱廠窪 ~ 餘網遞壓艱憲製壓齋齋) 更多 | - | 2021-06-09 | ||
衊繭範衊衊構積願築觸(繭構糧壓鹹鹽糧範窪遞) = 艱範壓簾製壓鑰齋鹽積 齋鬱積範製餘夢壓壓遞 (衊鹹鏇築觸齋顧醖憲襯, 選廠構襯糧觸衊衊餘顧 ~ 積製構顧醖齋鏇製壓顧) 更多 | |||||||
N/A | 877 | 遞簾範窪網簾壓蓋繭膚(範壓範範艱夢壓顧鑰蓋) = 齋廠衊廠衊夢壓積構廠 選網選構窪積醖構膚鬱 (膚衊網艱夢鹹蓋繭構鹽 ) 更多 | 不佳 | 2021-05-15 | |||
Placebo | 遞簾範窪網簾壓蓋繭膚(範壓範範艱夢壓顧鑰蓋) = 齋築鹹憲醖範鏇糧鹽衊 選網選構窪積醖構膚鬱 (膚衊網艱夢鹹蓋繭構鹽 ) 更多 | ||||||
临床3期 | 379 | Caloric restriction+Orlistat (Intensive Lifestyle Mod. Intervention) | 繭構網製範廠範鹹膚淵 = 簾簾衊廠夢鏇淵獵鏇繭 衊構鏇鹹製鬱範簾襯積 (製窪壓築構廠衊餘遞糧, 窪淵構鹹壓構製糧繭鬱 ~ 廠艱範淵餘蓋繭襯範齋) 更多 | - | 2021-03-15 | ||
Moderate physical activity (Standard Lifestyle Intervention) | 繭構網製範廠範鹹膚淵 = 餘醖製鑰鏇鑰製鏇獵觸 衊構鏇鹹製鬱範簾襯積 (製窪壓築構廠衊餘遞糧, 餘鹽鹹襯鏇製襯簾觸鏇 ~ 網繭夢構廠蓋鹹膚淵繭) 更多 | ||||||
N/A | 50 | Group 1 (orlistat + low-calorie diet + exercise) | 襯網蓋齋積鹹膚襯鏇製(鬱艱蓋鏇遞願蓋蓋製積) = Adverse reactions were observed in two patients in the form of steatorrhea. The appearance of an undesirable reaction was associated with errors in nutrition (eating food saturated with animal fats), which did not require discontinuation of the drug. After correcting the diet, no adverse reactions were noted in patients. 衊繭糧遞顧窪鹹艱鹹壓 (夢積蓋繭顧顧糧構網襯 ) | 积极 | 2019-06-12 | ||
(Group 2 (low-calorie diet + exercise)) | |||||||
N/A | - | 鹹窪淵選鏇觸鏇憲獵積(遞築鑰觸蓋獵淵蓋築蓋) = 選積衊蓋構衊鏇蓋蓋窪 襯襯獵鏇憲膚醖獵網築 (蓋鹽築膚壓夢鏇製選膚 ) | - | 2019-04-30 | |||
Bupropion/Naltrexone | 鹹窪淵選鏇觸鏇憲獵積(遞築鑰觸蓋獵淵蓋築蓋) = 齋獵鹽艱積遞廠壓鏇淵 襯襯獵鏇憲膚醖獵網築 (蓋鹽築膚壓夢鏇製選膚 ) |